Aberrant DNA methylation as a cancer-inducing mechanism

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 629-656

  Esteller, Manel ^a  

^a Centro Nacional de Investigations Oncológicas   (Spain)

Author keywords

5 Methylcytosine; CpG island; DNA demethylating agents; Hypomethylation; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; APC PROTEIN; AZACITIDINE; BETA CATENIN; BRCA1 PROTEIN; CARMUSTINE; DNA; DNA METHYLTRANSFERASE; DOXORUBICIN; ESTROGEN RECEPTOR; PROCAINAMIDE; PROCAINE; PROGESTERONE RECEPTOR; PROTEIN MLH1; PROTEIN P14; PROTEIN P15; PROTEIN P16INK4A; PROTEIN P53; PROTEIN P73; RETINOIC ACID RECEPTOR BETA; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; UBIQUITIN PROTEIN LIGASE; UVOMORULIN; ZEBULARINE;

CANCER CELL; CELL CYCLE; CPG ISLAND; DNA METHYLATION; DNA REPAIR; ENZYME ACTIVITY; EPIGENETICS; GENE INACTIVATION; GLIOMA; HUMAN; HUMAN CELL; HUMAN GENOME; LEUKEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA METHYLATION; HUMANS; NEOPLASMS;

EID: 13844320649     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.095832     Document Type: Review

References (147)

1. Feinberg AP, Vogeltein B. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89-92
2. Ehrlich M. 2000. DNA hypomethylation and cancer. In DNA Alterations in Cancer: Genetic and Epigenetic Changes, ed. M Ehrlich, pp. 273-91. Natick, MA: Eaton Publ.
3. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, et al. 2001. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 10:3001-7
4. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. 1989. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 83:155-58
5. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, et al. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91:9700-4
6. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:686-92
7. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, et al. 1995. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:4531-35
8. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, et al. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525-30
9. Clark SJ, Harrison J, Paul CL, Frommer M. 1994. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22:2990-97
10. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93:9821-26
11. Esteller M, Corn PG, Baylin SB, Herman JG. 2001. A gene hypermethylation profile of human cancer. Cancer Res. 61:3225-29
12. Fraga MF, Esteller M. 2002. DNA methylation: a profile of methods and applications. Biotechniques 33:632-49
13. Piyathilake CJ, Johanning GL, Frost AR, Whiteside MA, Manne U, et al. 2000. Immunohistochemical evaluation of global DNA methylation: comparison with in vitro radiolabeled methyl incorporation assay. Biotechnol. Histochem. 75:251-58
14. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, et al. 2004. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 64:5527-34
15. Fraga MF, Uriol E, Borja Diego L, Berdasco M, Esteller M, et al. 2002. High performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 23:1677-81
16. Bestor TH, Laudano A, Mattaliano R, Ingram V. 1988. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzyme is related to bacterial restriction methyltransferases. J. Mol. Biol. 203: 971-83
17. Yoder JA, Bestor TH. 1998. A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. Hum. Mol. Genet. 7:279-84
18. Hermann A, Schmitt S, Jeltsch A. 2003. The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity. J. Biol. Chem. 278:31717-21
19. Okano M, Xie S, Li E. 1998. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19:219-20
20. Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-57
21. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, et al. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404:1003-7
22. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, et al. 2004. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552-56
23. Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S. 2002. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J. 21:4183-95
24. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. 2003. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol. Cell Biol. 23:5594-605
25. Paz MF, Wei S, Cigudosa JC, Rodriguez-Perales S, Peinado MA, et al. 2003. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum. Mol. Genet. 12:2209-19
26. Tate PH, Bird AP. 1993. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3:226-31
27. Lee JH, Skalnik DG. 2002. CpG-binding protein is a nuclear matrix- and euchromatin-associated protein localized to nuclear speckles containing human trithorax. Identification of nuclear matrix targeting signals. J. Biol. Chem. 277: 42259-67
28. Kass SU, Pruss D, Wolffe AP. 1997. How does DNA methylation repress transcription? Trends Genet. 13:444-49
29. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, et al. 2002. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69:905-14
30. Meehan RR, Lewis JD, Bird AP. 1992. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20:5085-92
31. Hendrich B, Bird AP. 1998. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18:6538-47
32. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. 1999. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat. Genet. 23:62-66
33. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, et al. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19:187-91
34. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-89
35. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turne BM, et al. 1999. MBD2 is a transcriptional represser belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23:58-61
36. Ng HH, Jeppesen P, Bird A. 2000. Active repression of methylated genes by the chromosomal protein MBD1. Mol. Cell. Biol. 20:1394-406
37. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45
38. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. 2001. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 20:2536-44
39. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25:338-42
40. Fuks F, Kurd PJ, Deplus R, Kouzarides T. 2003. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 31:2305-12
41. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. 2003. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278:4035-40
42. Fujita N, Watanabe S, Ichimura T, Tsuruzoe S, Shinkai Y, et al. 2003. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J. Biol. Chem. 278:24132-38
43. Magdinier F, Wolffe AP. 2001. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc. Natl. Acad. Sci. USA 98:4990-95
44. Nguyen CT, Gonzales FA, Jones PA. 2001. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res. 29:4598-606
45. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, et al. 2003. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22:6335-45
46. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. 2003. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res. 31:1765-74
47. Paz MF, Avila S, Fraga MF, Pollan M, Capella G, et al. 2002. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 62:4519-24
48. Bird AP. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209-13
49. Esteller M. 2002. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427-40
50. Feinberg AP, Cui H, Ohlsson R. 2002. DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin. Cancer Biol. 12: 389-98
51. Yoder JA, Bestor TH. 1997. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13:335-40
52. Walsh CP, Chaillet JR, Bestor TH. 1998. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat. Genet. 20:116-17
53. Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, et al. 1999. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402:187-91
54. Feinberg AP. 1999. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res. 59(7 Suppl.):1743s-46
55. Plass C, Soloway PD. 2002. DNA methylation, imprinting and cancer. Eur. J. Hum. Genet. 10:6-16
56. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, et al. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205
57. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, et al. 2003. Induction of tumors in mice by genomic hypomethylation. Science 300:489-92
58. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, et al. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24:132-38
59. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, et al. 2002. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-82
60. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, et al. 2002. Cancer epigenetics and methylation. Science 297:1807-8
61. Herman JG, Jen J, Merlo A, Baylin SB. 1996. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56:722-27
62. Robertson KD, Jones PA. 1998. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell Biol. 18:6457-73
63. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, et al. 2000. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 60:129-33
64. Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, et al. 2001. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 61:2816-21
65. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, et al. 1999. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res. 59:3352-56
66. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, et al. 2000. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60:4366-71
67. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, et al. 1995. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55:5195-99
68. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, et al. 2001. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61:4556-60
69. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, et al. 2004. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36:417-22
70. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, et al. 1997. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57:808-11
71. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, et al. 1998. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 95: 6870-75
72. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. 1998. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17:2413-17
73. Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, et al. 1999. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol. 155:1767-72
74. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, et al. 1999. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 59:1090-95
75. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. 1999. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793-97
76. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. 2000. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60:2368-71
77. Esteller M, Risques RA, Toyota M, Capella G, Moreno V, et al. 2001. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 61:4689-92
78. Esteller M, Herman JG. 2004. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 8:1-8
79. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, et al. 2002. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21:2328-33
80. Esteller M, Suva JM, Dominguez G, Bonilla F, Matias-Guiu X, et al. 2000. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92:564-69
81. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, et al. 2001. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344:539-48
82. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. 1994. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54:2552-55
83. Lapidus RG, Ferguson AT, Ottaviano YL, Pari FF, Smith HS, et al. 1996. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res. 2:805-10
84. Jarrard DF, Kinoshita H, Shi Y, Hoff D, Meisner LF, et al. 1998. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 58:5310-14
85. Cote S, Momparler RL. 1997. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs 8:56-61
86. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, et al. 2000. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J. Natl. Cancer Inst. 92: 1303-7
87. Esteller M, Guo M, Moreno V, Peinado MA, Capella G, et al. 2002. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 62:5902-5
88. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, et al. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:29-35
89. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. 2003. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784-88
90. He B, You L, Uematsu K, Zang K, Xu Z, et al. 2003. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. USA 100:14133-38
91. Katzenellenbogen RA, Baylin SB, Herman JG. 1999. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93(12):4347-53
92. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. 2000. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res. 60:6236-42
93. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, et al. 2000. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 19:164-68
94. Dammann R, Li C, Yoon JH, Bates S, Pfeifer GP. 2000. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25:315-19
95. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, et al. 2001. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. 93:691-99
96. Irimia M, Sanchez-Cespedes M, Esteller M. 2004. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 23:In press
97. Li Q, Ahuja N, Burger PC, Issa JP. 1999. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 18:3284-89
98. Toyota M, Shen L, Ohe-Toyota M, Li Q, Ohe-Toyota M, et al. 2000. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 60:4044-48
99. Liang G, Robertson KD, Talmadge C, Sumegi J, Jones PA. 2000. The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells. Cancer Res. 60:4907-12
100. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, et al. 1994. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91:11733-37
101. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. 1998. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 58:4515-18
102. Akiyama Y, Watkins N, Suzuki H, Jair KW, van Engeland M, et al. 2003. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell Biol. 23:8429-39
103. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, et al. 2002. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2:485-95
104. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, et al. 2003. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat. Genet. 33:197-202
105. Kawai J, Hirotsune SK, Hirose K, Fushiki S, Watanabe S, Hayashizaki Y. 1993. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res. 21:5604-8
106. Gonzalgo ML, Liang G, Spruck CH 3rd, Zingg JM, Rideout WM 3rd, Jones PA. 1997. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res. 57:594-99
107. Toyota M, Ho C,Ahuja N, Jair KW, Li Q, et al. 1999. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 59:2307-12
108. Frigola J, Ribas M, Risques RA, Peinado MA. 2002. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res. 30: e28
109. Shiraishi M, Chuu YH, Sekiya T. 1999. Isolation of DNA fragments associated with methylated CpG islands in human adenocarcinomas of the lung using a methylated DNA binding column and denaturing gradient gel electrophoresis. Proc. Natl. Acad. Sci. USA 96:2913-18
110. Huang TH, Perry MR, Laux DE. 1999. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8:459-70
111. Gitan RS, Shi H, Chen CH, Yan PS, Huang TH. 2002. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res. 12:158-64
112. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, et al. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31:141-49
113. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, et al. 2001. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst. 93:1747-52
114. Esteller M. 2003. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 4:351-58
115. Laird PW. 2003. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3:253-66
116. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. 1999. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:67-70
117. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, et al. 2000. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:5954-58
118. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, et al. 2000. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 92:1511-16
119. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, et al. 2001. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J. Clin. Oncol. 19:299-304
120. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, et al. 2000. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343:1350-54
121. Balana C, Ramirez JL, Taron M, Roussos Y, Ariza A, et al. 2003. O6-methylguanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin. Cancer Res. 9:1461-68
122. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, et al. 2002. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94:26-32
123. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, et al. 2004. CpG island hypermethylation of the DNA repair enzyme MGMT predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 10:4933-38
124. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. 2000. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter. Cancer Res. 60:6039-44
125. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. 2001. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20:6597-606
126. Villar-Garea A, Esteller M. 2003. DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr. Drug. Metab. 4:11-31
127. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, et al. 2003. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63:1114-21
128. Nieto M, Samper E, Fraga MF, Gonzalez de Buitrago G, et al. 2004. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 23:735-43
129. Lin X, Asgari K, Putzi MJ, Gage WR, Yu X, et al. 2001. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61:8611-16
130. Villar-Garea A, Fraga MF, Espada J, Esteller M. 2003. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 63:4984-89
131. Jones PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93
132. Li LH, Olin EJ, Buskirk HH, Reineke LM. 1970. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 30:2760-69
133. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, et al. 1981. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res. 5:453-62
134. Foot M, Koehler J, Rabinovitch PS, Hoehn H, Priest JH. 1990. Cell kinetic disturbances induced by treatment of human diploid fibroblasts with 5-azacytidine indicate a major role for DNA methylation in the regulation of the chromosome cycle. Hum. Genet. 84:258-62
135. Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, et al. 2002. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J. Clin. Oncol. 20:2441-52
136. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, et al. 2002. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20:2429-40
137. Laliberte J, Marquez VE, Momparler RL. 1992. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother. Pharmacol. 30:7-11
138. Ho DH. 1973. Distribution of kinase andand deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res. 33:2816-20
139. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, et al. 2003. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 95:399-409
140. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell Biol. 24:1270-78
141. Wijermans PW, Krulder JW, Huijgens PC, Neve P. 1997. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1-5
142. Schwartsmann G, Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, et al. 1997. Decitabine (5-aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 11(Suppl. 1): S28-31
143. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, et al. 2000. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J. Clin. Oncol. 18:956-62
144. Ballestar E, Esteller M. 2002. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23:1103-9
145. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, et al. 2002. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-64
146. Lo Coco F, Zelent A, Kimchi A, Carducci M, Gore SD, Waxman S. 2002. Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond. Cancer Res. 62:5618-21
147. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, et al. 2001. Inactivation of the apoptosis effector Apaf-1 in melanoma. Nature 409:207-11